Outcomes With Combined Laser Atherectomy and Intravascular Brachytherapy in Recurrent Drug-Eluting Stent In-Stent Restenosis

• Published in: Cardiovascular revascularization medicine 2021-01, Vol.22, p.29-33
• Main Authors: Megaly, Michael, Glogoza, Matthew, Xenogiannis, Iosif, Vemmou, Evangelia, Nikolakopoulos, Ilias, Omer, Mohamed, Willson, Laura, Monyak, David J., Sullivan, Patsa, Stanberry, Larissa, Chavez, Ivan, Mooney, Michael, Traverse, Jay, Wang, Yale, Garcia, Santiago, Poulose, Anil, Burke, M. Nicholas, Brilakis, Emmanouil S.
• Format: Article
• Language: English
• Subjects: ELCA; In-stent restenosis; Intravascular brachytherapy; ISR; IVBT; Laser atherectomy; Vascular brachytherapy; VBT
• ISSN: 1553-8389; 1878-0938
• DOI: 10.1016/j.carrev.2020.06.019

Recurrent drug-eluting stents (DES) in-stent restenosis (ISR) can be challenging to treat. The combined use of excimer laser atherectomy (ELCA) and vascular brachytherapy (VBT) for this indication has received limited study. We report the long-term outcomes of patients with recurrent DES ISR treated with combined VBT and ELCA from January 2014 to September 2018 at a single institution. Outcomes included target lesion failure (TLF), defined as the composite of clinically driven target lesion revascularization (TLR), target lesion myocardial infarction (MI), and target lesion-related cardiac death. During the study period, 116 patients (143 lesions) underwent VBT, of which 19 patients (19 lesions) underwent combined laser atherectomy and VBT. All procedures were successful without no-reflow or dissection. Two propensity-score matched cohorts (ELCA + VBT (n = 18) vs. VBT only (n = 18)) were compared. During a median follow-up of 25.5 (14.5–40) months, there was no difference in the incidence of TLF (38.9% vs. 38.9%, log-rank p = 0.688), target-lesion MI (5.6% vs. 5.6%, log-rank p = 0.915), or TLR (38.9% vs. 33.3%, log-rank p = 0.933) between both groups. There was no cardiac death related to the target lesion. When compared with VBT alone for the treatment of resistant DES ISR, combined use of ELCA and brachytherapy is associated with comparable long-term outcomes. ELCA should be considered in ISR lesions due to stent underexpansion. •ELCA combined with VBT is a safe tool in the treatment of resistant DES ISR.•The rate of TLF in recurrent ISR treated with combined VBT and ELCA is high (38%).•ELCA can be considered in ISR lesions due to underexpanded stents.